ACLS Pharmacology Summary Table

First drug for most forms of stable narrow-complex SVT; effective in terminating those due to reentry involving AV node or sinus node

Because its use is associated with toxicity, it is indicated for use in patients with life-threatening arrhythmia when administered with appropriate monitoring:
-VF/pulseless VT unresponsive to shock delivery, CPR and a vasopressin
-recurrent, hemodynamically unstable VT
With expert consultation, it may be used for treatment of some atrial and ventricular arrhthmias

Atropine sulfate
First drug for symptomatic sinus bradycardia
Maybe be beneficial in presence of AV nodal block
Organophosphate (ex: nerve agent) poisoning: extremely large doses may be needed

Second-line drug for symptomatic bradycardia (after atropine)
Use for hypotension (SBP < 70 to 100 mmHg) with signs/symptoms of shock

Cardiac arrest: VF, pulseless VT, PEA
Symptomatic bradycardia: can be considered after atropine as an alternative infusion to dopamine
Severe hypotension: can be used when pacing and atropine fail, when hypotension accompanies bradycardia, or with phosphodiesterase enzyme inhibitor
Anaphylaxis, severe allergic reactions: combine with large fluid volume, corticosteroids, antihistamines

Alternative to amiodarone in cardiac arrest from VF/pVT
Stable monomorphic VT with preserved ventricular function
Stable polymorphic VT with normal baseline QT interval and preserved LV function when ischemia is treated and electrolyte balance is corrected
Can be used for stable polymorphic VT with baseline
QT-interval prolongation if torsades suspected

Magnesium sulfate
Recommended for use in cardiac arrest only if torsades de pointers or suspected hypomagnesemia is present
Life-threatening ventricular arrhythmias due to digitalis toxicity
Routine administration in hospitalized patients with AMI is not recommended

Adenosine – Indications – First drug for most forms of stable narrow-complex SVT – Effective in terminating reentry involving AV node/sinus node – Narrow-complex reentry tachycardia while prepping for cardioversion – Wide-complex tachycardia, thought to be reentry SVT – Doesn’t …

ADENOSINE indications for use *First drug for most forms of stable narrow complex SVT. *Effective in terminating those due to reentry involving AV node or sinus node. AMIODARONE indications for use *VF/pulseless VT unresponsive to shock delivery, CPR, and a …

What are the goals of ACLS? restoration of spontaneous ventilation and circulation Cerebral perfusion and resuscitation What is Class I benefit>>> risk? procedure/treatment or diagnostic test/assessment should be performed/administered WE WILL WRITE A CUSTOM ESSAY SAMPLE ON ANY TOPIC SPECIFICALLY …

Adenosine Indication: stable narrow complex SVT Precaution: posion/drug induce tachycardia or 2 or 3 degree heart block Route: IV rapid push Dosage: 6 mg follow by a 20mL of NS raise extremity, second dosage of 12 mg if needed, 1-2min …

VF/ pulseless VT drugs Epinephrine IV/IO (1mg q3-5min) Vasopressin IV/IO (40u can replace first or second dose of EPI Amiodarone IV/IO (First dose: 300mg bolus. 2nd dose: 150mg) Asystole/PEA drugs Epinephrine IV/IO (1mg q3-5min) Vasopressin IV/IO (40u can replace first …

Adenosine • SVT • 0.1 mg/kg IV/IO rapid push (max 6 mg) • 2nd dose 0.2 mg/kg IV/IO rapid push (max 12 mg) Albumin • Shock, Trauma, Burns • 0.5 to 1 g/kg (10-20 ml/kg of 5% solution) IV/IO rapid …

David from Healtheappointments:

Hi there, would you like to get such a paper? How about receiving a customized one? Check it out